茶叶中EGCG对非酒精性脂肪肝大鼠的调脂保肝作用研究

doi:10.13305/j.cnki.jts.2014.03.003

摘要/Abstract

摘要： 非酒精性脂肪肝是以肝实质细胞发生脂肪堆积和脂肪变性为主要特征,并伴随机体脂质代谢紊乱的一种获得性代谢疾病。以高脂饲料喂养大鼠,建立非酒精性脂肪肝大鼠模型;以低、中、高剂量（10、50、100 mg·kg^-1）表没食子儿茶素没食子酸酯（EGCG）分别灌胃模型大鼠,探讨茶叶中EGCG对非酒精性脂肪肝大鼠的调脂保肝作用。结果表明,与模型组相比,EGCG能显著降低血清中甘油三酯（TG）、总胆固醇（TC）和低密度脂蛋白-胆固醇（LDL-C）含量,降低丙氨酸氨基转移酶（ALT）和天冬氨酸转氨酶（AST）活性水平,提高高密度脂蛋白-胆固醇（HDL-C）的含量,改善大鼠肝脏氧化应激状态。此外,肝脏病理切片显示,EGCG能减少肝细胞中脂滴的形成,同时脂质代谢相关基因表达量分析显示,EGCG能调理肝脏的脂质代谢。综合以上实验结果表明,EGCG能显著改善非酒精性脂肪肝大鼠的脂质代谢紊乱和脂肪性肝损伤。

关键词: 茶叶, 表没食子儿茶素没食子酸酯, 非酒精性脂肪肝, 脂质代谢紊乱, 肝损伤, 改善作用

Abstract: Non-alcoholic fatty liver disease (NAFLD) is a pathological metabolic syndrome performed as the fat accumulation and/or fatty degeneration in the liver, which is directly relevant to lipid metabolic disorder. In order to investigate the effects of EGCG from tea on regulating lipid metabolism and alleviating liver injury in rats with NAFLD, NAFLD model rats were established by feeding a high fat diet, and then the rats of EGCG protective groups were given daily oral administration of EGCG with three doses of 10, 50 mg·kg^-1 and 100 mg·kg^-1, respectively. The results showed that, compared with the model group, EGCG could decrease serum levels of triglyceride (TG), total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C), increase serum level of high density lipoprotein-cholesterol (HDL-C), reduce activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the serum, and ameliorate liver oxidative stress. Also, histological analysis showed that EGCG could reduce the formation of lipid droplets in the liver cells, and RT-PCR analysis showed that EGCG could regulate the expression of genes involved in lipid metabolism. Taken together, these experiment results indicated that GCG from tea effectively alleviate lipid metabolic disorder and lipid-induced liver injury.

Key words: tea, EGCG, NAFLD, lipid metabolism disorder, liver injury, alleviative effect

中图分类号:

严煜钧, 刘仲华, 林勇, 黄建安, 彭彬, 蒋华军. 茶叶中EGCG对非酒精性脂肪肝大鼠的调脂保肝作用研究[J]. 茶叶科学, 2014, 34(3): 221-229. doi: 10.13305/j.cnki.jts.2014.03.003.

YAN Yujun, LIU Zhonghua, LIN Yong, HUANG Jian′an, PENG Bin, JIANG Huajun. Effects of EGCG from Tea on Regulating Lipid Metabolism and Alleviating Liver Injury in Rats with Non-alcoholic Fatty Liver Disease[J]. Journal of Tea Science, 2014, 34(3): 221-229. doi: 10.13305/j.cnki.jts.2014.03.003.

参考文献 34

[1]	WOLFRAM S.Effects of green tea and EGCG on cardiovascular and metabolic health[J]. Journal of the American College of Nutrition, 2007, 26(4): 373S-388S.
[2]	KAO Y H, CHANG H H, LEE M J, et al. Tea, obesity, and diabetes[J]. Molecular Nutrition & Food Research, 2006, 50(2): 188-210.
[3]	SHIMOTOYODOME A, HARAMIZU S, INABA M, et al. Exercise and green tea extract stimulate fat oxidation and prevent obesity in mice[J]. Medicine and Science in Sports and Exercise, 2005, 37(11): 1884.
[4]	PARK H J, DINATALE D A, CHUNG M-Y, et al. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice[J]. The Journal of Nutritional Biochemistry, 2011, 22(4): 393-400.
[5]	葛建, 林芳, 李明揆, 等. 表没食子儿茶素没食子酸酯(EGCG)生物活性研究进展[J]. 安徽农业大学学报, 2011, 38(2): 156-163.
[6]	赵丽萍, 邵宛芳. 茶叶中EGCG功效研究进展[J]. 中国农学通报, 2007, 27(7): 143-147.
[7]	毛清黎, 施兆鹏, 李玲, 等. 茶叶儿茶素保健及药理功能研究新进展[J]. 食品科学, 2007, 28(8): 584-589.
[8]	程金勇, 毛清黎, 匡逢春, 等. 茶叶儿茶素保健及药理功能研究进展[J]. 茶叶通讯, 2007, 34(2): 14-18.
[9]	仉燕崃, 李楠, 韩国柱, 等. 表没食子儿茶素没食子酸酯的研究进展[J]. 中草药, 2006, 37(2): 303-306.
[10]	宛晓春. 茶叶生物化学 [M]. 北京:中国农业出版社, 2006.
[11]	LI L, CHAN T H.Enantioselective synthesis of epigallocatechin-3-gallate (EGCG), the active polyphenol component from green tea[J]. Organic Letters, 2001, 3(5): 739-741.
[12]	JUNG Y D, ELLIS L M.Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea[J]. International Journal of Experimental Pathology, 2001, 82(6): 309-316.
[13]	PASCHKA A G, BUTLER R, YOUNG C Y-F. Induction of apoptosis in prostate cancer cell lines by the green tea component,(-)-epigallocatechin-3-gallate[J]. Cancer Letters, 1998, 130(1): 1-7.
[14]	中华人民共和国卫生部. 保健食品检验与评价技术规范[M]. 北京: 中华人民共和国卫生部卫生法规与监督司, 2003.
[15]	CHEN N, BEZZINA R, HINCH E, et al. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet[J]. Nutrition Research, 2009, 29(11): 784-793.
[16]	NSEIR W, MOGRABI J, GHALI M.Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human Studies[J]. Dig Dis Sci, 2012, 57(7): 1773-1781.
[17]	MARCHESINI G, BUGIANESI E, FORLANI G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome[J]. Hepatology, 2003, 37(4): 917-923.
[18]	CHANG T-Y, LI B-L, CHANG C C Y, et al. Acyl-coenzyme A:cholesterol acyltransferases[J]. American Journal of Physiology - Endocrinology And Metabolism, 2009, 297(1): E1-E9.
[19]	窦晓兵. 卵磷脂胆固醇酰基转移酶(LCAT)的基因突变与LCAT缺陷综合征[J]. 国外医学: 分子生物学分册, 2003, 25(5): 311-315.
[20]	CHOI S S, DIEHL A M.Hepatic triglyceride synthesis and nonalcoholic fatty liver disease[J]. Curr Opin Lipidol, 2008, 19(3): 295-300.
[21]	CHOI C S, SAVAGE D B, KULKARNI A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance[J]. The Journal of Biological Chemistry, 2007, 282(31): 22678-22688.
[22]	BROWNING J D, HORTON J D.Molecular mediators of hepatic steatosis and liver injury[J]. J Clin Invest, 2004, 114(2): 147-152.
[23]	AN J, MUOIO D M, SHIOTA M, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance[J]. Nature Medicine, 2004, 10(3): 268-274.
[24]	FAN J G, DING X D, WANG G L, et al. Expression of uncoupling protein 2 and its relationship to the content of adenosine triphosphate in the nonalcoholic fatty livers of rats fed a high-fat diet[J]. Chinese journal of Hepatology, 2005, 13(5): 374-377.
[25]	顾小红, 张云东, 冯爱娟. 解偶联蛋白-2在大鼠非酒精性脂肪肝中的表达[J]. 世界华人消化杂志, 2005, 13(19): 2310-2313.
[26]	MATTEONI C A, YOUNOSSI Z M, GRAMLICH T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity[J]. Gastroenterology, 1999, 116(6): 1413-1419.
[27]	范建高, 曾民德, 王国良. 脂肪肝的发病机制[J]. 世界华人消化杂志, 1999, 7(1): 75.
[28]	YAMAMOTO T, STAPLES J, WATAHA J, et al. Protective effects of EGCG on salivary gland cells treated with γ-radiation or cis-platinum (II) diammine dichloride[J]. Anticancer Research, 2004, 24(5A): 3065-3074.
[29]	GUPTA S, HUSSAIN T, MUKHTAR H.Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells[J]. Archives of Biochemistry and Biophysics, 2003, 410(1): 177-185.
[30]	CHUNG J H, HAN J H, HWANG E J, et al. Dual mechanisms of green tea extract (EGCG)-induced cell survival in human epidermal keratinocytes[J]. The FASEB Journal, 2003, 17(13): 1913-1915.
[31]	CANIPAROLI J, GAINS N, ZULAUF M.Influence of stigmastanyl phosphorylcholine on the size, mass, and shape of taurocholate/lecithin/cholesterol mixed micelles[M]. Trends in Colloid and Interface Science VI. Springer, 1992: 268-270.
[32]	RAEDERSTORFF D G, SCHLACHTER M F, ELSTE V, et al. Effect of EGCG on lipid absorption and plasma lipid levels in rats[J]. The Journal of Nutritional Biochemistry, 2003, 14(6): 326-332.
[33]	孙世利, 凌彩金, 潘顺顺, 等. 茶叶抑制肥胖的生物化学与分子细胞生物学机制[J]. 中国农学通报, 2011, 27(2): 373-377.
[34]	MASTERJOHN C, BRUNO R S.Therapeutic potential of green tea in nonalcoholic fatty liver disease[J]. Nutrition Reviews, 2012, 70(1): 41-56.